Article

Single cell profiling of del(5q) MDS unveils its transcriptional landscape and the impact of lenalidomide

2023-10-20

Abstract excerpt

<h4>ABSTRACT</h4> While del(5q) MDS patients comprise a well-defined hematological subgroup, the molecular basis underlying its origin, and the reason behind the relapse after lenalidomide remains unknown. Using scRNA-seq on CD34 + progenitor cells from patients with del(5q) MDS we were able to identify cells harboring the deletion, enabling us to deeply characterize the transcriptional impact of this genetic in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 939cbff5-76a9-503b-944b-8b269bb7f4e4
DOI: 10.1101/2023.10.19.562875

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Single cell profiling of del(5q) MDS unveils its transcriptional landscape and the impact of lenalidomideDOI 10.1101/2023.10.19.562875Read

Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomideSemantic proximity Read

Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.Semantic proximity Read

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid MalignanciesSemantic proximity Read

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discoverySemantic proximity Read

Lenalidomide inhibits the malignant clone and up-regulates the <i>SPARC</i> gene mapping to the commonly deleted region in 5q− syndrome patientsSemantic proximity Read

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.Semantic proximity Read

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Semantic proximity Read

Deletion 5q MDS: molecular and therapeutic implications.Semantic proximity Read

Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.Semantic proximity Read

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progressionSemantic proximity Read

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.Semantic proximity Read

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read